Dr. David Agus of USC reported on research conducted at Sloan Kettering which used targeted T cell therapy to treat 16 patients suffering from “They took 16 patients with advanced leukemia, who had failed chemotherapy or not responded at all to chemotherapy, so they classically have weeks to months to live. They took their own immune cells out… and inserted a homing mechanism to target the cancer cells,” said Agus. “The cancer cells were growing on their own, unrelentingly, and these immune cells came in and they could target and kill them. They become assassins. So, making their own immune cells become assassins and it worked.”
|